Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Eurasian Patent Organization: These 31 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Eurasian Patent Organization: These 31 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZTALMY (ganaxolone) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,290
Patent Title: КОМПОЗИЦИИ НА ОСНОВЕ ГАНАКСОЛОНА (GANAXOLONE-BASED FORMULATIONS)

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,091

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,532

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,252

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,966

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,557

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,687

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,688

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,545
Patent Title: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ (THERAPEUTIC COMPOSITIONS)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 24,152
Patent Title: КОМПОЗИЦИЯ ДЛЯ МЕСТНОГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА КОЖИ (TOPICAL COMPOSITION FOR TREATING OR PREVENTING SKIN CANCER)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,063
Patent Title: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,201,452
Patent Title: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 27,573

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 34,598

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,116

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,790,678

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the Eurasian Patent Organization?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,275
Patent Title: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the Eurasian Patent Organization?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,725
Patent Title: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,726

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in the Eurasian Patent Organization?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,896
Patent Title: ТВЕРДАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ПРОИЗВОДНОЕ БЕНЗИМИДАЗОЛ-7-КАРБОКСИЛАТА И pH РЕГУЛИРУЮЩИЙ АГЕНТ (SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT)

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in the Eurasian Patent Organization?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 29,890

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,883

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 34,294

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,400,387

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,991,590

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,514

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,515

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,270

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,046

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,203

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,284

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,132

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,284

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,132

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can XADAGO (safinamide mesylate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: safinamide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 25,326

Drug Price Trends for XADAGO
XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. Additional details are available on the safinamide mesylate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,784

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,013

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in the Eurasian Patent Organization?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,806
Patent Title: СИНТЕТИЧЕСКАЯ ДЕЗОКСИХОЛЕВАЯ КИСЛОТА И КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОЕДИНЕНИЯ И СПОСОБ ПОЛУЧЕНИЯ ДЕЗОКСИХОЛЕВОЙ КИСЛОТЫ, СПОСОБ УДАЛЕНИЯ ЖИРОВЫХ ОТЛОЖЕНИЙ (METHOD FOR PRERARING DEOXYCHOLIC ACID (EMBODIMENTS), DEOXYCHOLIC ACID PREPARED BY SAID METHOD, PHARMACEUTICAL COMPOSITION CONTAINING SAME, METHOD FOR REMOVAL OF FAT DEPOSITS)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in the Eurasian Patent Organization?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,032
Patent Title: СПОСОБ ПОЛУЧЕНИЯ ДЕЗОКСИХОЛЕВОЙ КИСЛОТЫ (ВАРИАНТЫ), ДЕЗОКСИХОЛЕВАЯ КИСЛОТА, ПОЛУЧЕННАЯ УКАЗАННЫМ СПОСОБОМ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕЕ СОДЕРЖАЩАЯ, СПОСОБ УДАЛЕНИЯ ЖИРОВЫХ ОТЛОЖЕНИЙ (METHOD FOR PRERARING DEOXYCHOLIC ACID (EMBODIMENTS), DEOXYCHOLIC ACID PREPARED BY SAID METHOD, PHARMACEUTICAL COMPOSITION CONTAINING SAME, METHOD FOR REMOVAL OF FAT DEPOSITS)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,123
Patent Title: УСТРОЙСТВО ДОСТАВКИ В КОЖУ С ИЗОЛИРУЮЩИМ СЛОЕМ IN SITU (DERMAL DELIVERY DEVICE WITH IN SITU SEAL)

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,093
Patent Title: ПРОИЗВОДНЫЕ ПИРИДАЗИНОНА (PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,094
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИНИЛПИРИДАЗИНОНА (PYRIMIDINYL PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,870

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,164

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,018

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,298
Patent Title: ИНГИБИТОРЫ ВИРУСА ГЕПАТИТА С (HEPATITIS C VIRUS INHIBITORS)

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,405

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,941

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,824
Patent Title: АНТИБАКТЕРИАЛЬНЫЕ АНАЛОГИ АМИНОГЛИКОЗИДА (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,597
Patent Title: АНТИБАКТЕРИАЛЬНЫЕ АНАЛОГИ АМИНОГЛИКОЗИДА (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 23,500

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,440

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,441

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,270,666

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 23,500

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,440

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,441

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,270,666

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,839
Patent Title: ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-С]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,733
Patent Title: ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,698

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,150

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,575

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,697

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,757

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Eurasian Patent Organization Drug Markets: Branded and Generic Regulatory Assessment

Last updated: October 13, 2026

The Eurasian Patent Organization (EAPO) creates a regional patent route across eight Eurasian jurisdictions, but it does not regulate medicines or create a single pharmaceutical market. Drug authorization and market access depend primarily on national regulators and, for the Eurasian Economic Union (EAEU), the EAEU pharmaceutical framework. The commercial opportunity is strongest in Russia, Kazakhstan and Belarus, while regulatory fragmentation, sanctions, local manufacturing rules, currency controls and uneven enforcement raise execution risk.

What countries are covered by the Eurasian Patent Organization?

EAPO administers the Eurasian Patent Convention and grants a single Eurasian patent that can have effect in its contracting states.

EAPO contracting state EAEU member? Primary commercial relevance
Armenia Yes Small pharmaceutical market; EAEU registration framework
Azerbaijan No Separate national regulatory and patent systems
Belarus Yes State-influenced procurement; local production policies
Kazakhstan Yes Regional hub; EAEU and national procurement significance
Kyrgyzstan Yes Smaller market; EAEU regulatory alignment
Russia Yes Largest market in the EAPO region; extensive local-production policy
Tajikistan No National regulatory pathway
Turkmenistan No Restricted and less transparent market

EAPO currently has eight contracting states. EAEU membership is narrower, covering Armenia, Belarus, Kazakhstan, Kyrgyzstan and Russia. This distinction is central to pharmaceutical strategy. A Eurasian patent does not replace national marketing authorization, pharmacovigilance, pricing, reimbursement or procurement requirements.

What is the difference between EAPO patents and EAEU drug regulation?

EAPO governs industrial-property protection. The EAEU governs the common pharmaceutical regulatory framework in its five member states.

Issue EAPO system EAEU system
Core function Patent examination and grant Medicine registration and circulation
Covered jurisdictions Eight EAPO states Five EAEU states
Product approval No Yes, through EAEU or national transition mechanisms
Patent examination Centralized at EAPO Not applicable
Generic approval No Yes, under EAEU rules
Patent linkage No uniform EAPO linkage system No fully harmonized automatic linkage system
Pharmacovigilance No Yes, under EAEU rules
Patent litigation National courts and procedures National courts
Pricing and reimbursement National Primarily national

An EAPO patent can reduce filing and prosecution complexity compared with separate national applications. Enforcement remains territorial. Patent litigation, injunctions, customs measures and damages depend on the laws and courts of the country where infringement occurs.

What patents protect branded drugs in the EAPO region?

Branded medicines are typically protected by a layered patent estate rather than a single patent.

Core composition patents

A composition-of-matter patent protects the active pharmaceutical ingredient or a defined chemical class. This is usually the strongest patent category for a new small-molecule medicine. The standard patent term is generally 20 years from the relevant filing date, subject to the applicable national and treaty rules.

For biologics, protection may cover the amino-acid sequence, nucleic-acid sequence, engineered variants, antibody structure, host cell or production system. The practical strength of these claims depends on disclosure quality and the ability to prove infringement.

Formulation patents

Formulation patents can protect:

  • Extended-release tablets
  • Long-acting injectables
  • Liposomal or nanoparticle delivery
  • Stabilized protein formulations
  • Device-integrated delivery systems
  • Specific excipient combinations
  • Solubility-enhanced or amorphous forms
  • Pediatric or abuse-deterrent formulations

Formulation patents are commercially important after core compound protection weakens. Their value depends on whether a generic or biosimilar can design around the claims while maintaining regulatory equivalence.

Method-of-use patents

Method-of-use patents can cover treatment of a particular disease, patient population, biomarker-defined group, dosing schedule or combination therapy. Their enforcement against a generic depends on product labeling, promotional conduct, prescribing behavior and national patent law.

A generic applicant may seek approval for non-patented uses where the regulatory framework permits a partial or carve-out approach. The availability and practical effectiveness of such strategies differ by jurisdiction.

Manufacturing and process patents

Process patents may protect:

  • A stereoselective synthesis
  • A crystalline form produced by a defined process
  • A biologic cell line
  • Purification or conjugation steps
  • A continuous manufacturing process
  • A high-yield intermediate

These patents can create supply-chain barriers even when a generic product obtains marketing authorization. They are harder to monetize if the relevant process is not publicly visible or if infringement is difficult to prove.

How many patents cover a typical branded medicine?

There is no reliable single number across the EAPO region. A small-molecule medicine may have one core compound patent and several secondary patents covering salts, polymorphs, formulations, methods of treatment and manufacturing. A biologic may have a broader estate covering the molecule, sequence, formulation, cell line, manufacturing process and delivery device.

Patent counting also creates analytical risk. The same invention may appear as:

  • A national filing
  • An EAPO application
  • A continuation or divisional
  • A national validation
  • A supplementary or improvement patent
  • A later patent directed to a formulation or use

A proper freedom-to-operate review should therefore distinguish patent families, enforceable national rights and claims relevant to the proposed product.

When do branded medicines lose exclusivity in EAPO markets?

Loss of exclusivity depends on three separate events:

  1. Expiration or invalidation of relevant patents.
  2. Expiration of regulatory data or market exclusivity.
  3. Actual approval, supply and reimbursement of a competing product.

Patent expiry does not guarantee immediate generic entry. A competitor may face registration delays, local clinical or comparability requirements, procurement restrictions, manufacturing qualification and price controls.

For small molecules, the commercial entry date is usually driven by the earliest enforceable patent that covers the proposed product or its intended use. For biologics, biosimilar entry depends on reference-product exclusivity, comparability evidence, manufacturing capacity and substitution rules.

EAPO patent timing

Eurasian patents generally have a 20-year term from the filing date, subject to the governing legal framework. Patent term calculations must account for:

  • Priority date
  • Filing date
  • International applications
  • Divisional applications
  • National validation and maintenance
  • Patent restoration or extension mechanisms, where available
  • Claim scope after opposition or litigation

EAPO does not create a region-wide pharmaceutical patent-term-extension system equivalent to a single European supplementary protection certificate. Regulatory and patent-term analysis must therefore be performed country by country.

What is the Orange Book status of medicines in EAPO countries?

There is no single EAPO or EAEU equivalent to the U.S. Food and Drug Administration’s Orange Book.

Patent listing and generic certification procedures are handled through national systems and EAEU regulatory mechanisms. The absence of a unified Orange Book has several consequences:

  • Reference-product patents may not be displayed in one authoritative database.
  • Generic applicants may need separate patent-risk analyses.
  • Patent and regulatory review may occur in parallel rather than through a transparent linkage process.
  • Innovators have less certainty about when they will receive notice of a challenge.
  • Third parties must reconcile patent registers, medicine registers, court decisions and regulatory records.

This increases the value of local patent monitoring. EAPO records should be reviewed together with national registers, EAEU medicine databases and court filings.

Which companies are challenging branded medicines?

Company-specific challenge mapping cannot be made reliably without a defined active ingredient, reference product and jurisdiction. The market generally includes four challenger groups:

Domestic generic manufacturers

Russian, Belarusian and Kazakh manufacturers are the principal source of generic competition in the EAEU. They often compete through public procurement, local manufacturing programs and lower-cost supply.

Regional pharmaceutical groups

Companies with operations across Russia, Kazakhstan, Belarus and Armenia can use shared commercial infrastructure while adapting regulatory and procurement strategies to each country.

Indian and Chinese manufacturers

Indian and Chinese companies can compete in active pharmaceutical ingredients, finished-dose products, contract manufacturing and biosimilar development. Market access depends on registration, local representation, supply continuity and geopolitical restrictions.

State-linked and contract manufacturers

Government-supported producers may receive procurement advantages, investment incentives or localization support. These advantages can be commercially significant even when patent positions are weak.

How do Paragraph IV challenges work in the EAPO region?

The U.S. Paragraph IV certification model does not operate as a single EAPO-wide procedure. A challenger may instead use national invalidity actions, non-infringement positions, pre-approval litigation, regulatory submissions or post-launch defenses.

The principal litigation questions are usually:

  • Whether the patent is valid.
  • Whether the proposed product falls within the claims.
  • Whether the patent is enforceable in the relevant country.
  • Whether the generic application or launch creates actionable infringement.
  • Whether the claimed use is included in the product label.
  • Whether a national regulator will approve the product before patent expiry.

Patent challenges can be initiated by generic manufacturers, distributors or other parties with standing under national law. Litigation strategy must be localized because evidence standards, court expertise, injunction practice and appeal timelines differ across jurisdictions.

What biosimilar risks exist in EAPO and EAEU markets?

Biosimilar risk is increasing but is less predictable than conventional generic risk.

The main barriers are:

  • High development and manufacturing costs
  • Limited biologics capacity in some EAEU states
  • Comparability and immunogenicity requirements
  • Complex analytical characterization
  • Reference-product sourcing
  • Substitution and interchangeability rules
  • Patent protection for formulations and manufacturing processes
  • Procurement decisions based on price and local supply

Russia has the largest biosimilar commercial opportunity in the EAPO region. Kazakhstan can provide a regional distribution and manufacturing base. Belarus has a significant state role in procurement and industrial policy. Armenia and Kyrgyzstan are smaller markets but may be relevant for regional registration and supply arrangements.

Biosimilar developers should assess the complete patent estate, not only patents covering the reference molecule. Formulation, device, production and treatment-method claims can create launch constraints after the primary biologic patent expires.

What is the FDA regulatory status of medicines sold in EAPO countries?

FDA status is not a prerequisite for EAPO or EAEU approval. A medicine may be authorized in an EAEU state without U.S. approval, and FDA approval does not guarantee EAEU authorization.

FDA approval can support credibility, clinical-development strategy and regulatory reliance discussions, but the product still must satisfy applicable EAEU or national requirements. Key differences may involve:

  • Clinical-trial data acceptance
  • Manufacturing-site inspection
  • Good Manufacturing Practice compliance
  • Stability data
  • Labeling and product information
  • Pharmacovigilance systems
  • Batch release
  • Local representative requirements
  • Translation and serialization

For non-EAEU EAPO states, national regulatory requirements apply independently.

What licensing deals create opportunity in EAPO drug markets?

Licensing and partnership opportunities are concentrated in five areas:

Opportunity Commercial rationale
Local manufacturing license Reduces import exposure and may improve procurement eligibility
Technology transfer Supports biosimilars, sterile injectables and complex generics
Regional distribution Provides access to fragmented national markets
Co-development Shares clinical, regulatory and manufacturing costs
In-licensing of off-patent products Targets supply gaps and hospital procurement demand

Licenses should define territory carefully. An EAPO patent territory is not identical to the EAEU commercial territory. The agreement should address patent prosecution, enforcement, regulatory ownership, pharmacovigilance, sanctions compliance, currency controls, compulsory licensing and change-of-law risk.

What regulatory opportunities exist for branded and generic companies?

Branded companies

The main opportunities are:

  • Centralized EAEU registration for access to multiple member states
  • Local production partnerships
  • Licensing of established products to regional manufacturers
  • Orphan and specialty medicines
  • Oncology, immunology, diabetes and rare-disease products
  • Lifecycle management through formulations and delivery devices

Generic companies

Generic manufacturers can target:

  • Products with expired core patents
  • Medicines affected by supply shortages
  • Hospital and state procurement
  • Complex injectables
  • Modified-release formulations
  • Biosimilars
  • Products with weak secondary-patent coverage
  • Local manufacturing incentives

The strongest commercial position generally combines regulatory approval, dependable manufacturing, competitive pricing and access to procurement channels.

What regulatory and patent challenges affect market entry?

Fragmented enforcement

Patent rights may be granted centrally through EAPO but enforced nationally. A favorable result in one country does not automatically resolve disputes elsewhere.

Local-production policy

EAEU states may favor domestic manufacturing through procurement preferences, investment programs, industrial policy and supply-security measures. These policies can disadvantage imported products without formally blocking them.

Sanctions and supply-chain constraints

Restrictions involving Russia and Belarus affect payments, logistics, technology transfer, insurance, clinical supplies and banking. Sanctions screening is necessary for licensors, distributors, contract manufacturers and service providers.

Data and transparency limitations

Patent, court, procurement and regulatory information may be less accessible or less standardized than in the United States or European Union. Commercial forecasts should apply a higher verification burden to patent status and launch timing.

Regulatory transition

The EAEU pharmaceutical system has involved transition periods between national approvals and common-market procedures. Companies must verify the applicable pathway and deadline for each product rather than rely on a general EAEU assumption.

How does the EAPO market compare with European and U.S. markets?

Factor EAPO and EAEU region European Union United States
Patent grant Central EAPO route available European Patent Convention route U.S. national system
Drug authorization EAEU or national pathways EMA and national pathways FDA
Patent linkage Fragmented Varies by country Structured Orange Book system
Generic challenge Nationally variable National litigation systems Hatch-Waxman framework
Pricing Strong national control National reimbursement systems More market-driven, though payer pressure is high
Procurement State and institutional purchasing is important National and hospital tenders Private and public payer mix
Biosimilar substitution Country-specific More developed in several states State and payer dependent
Enforcement predictability Lower and more variable Generally higher High but costly
Localization pressure Material in EAEU markets Present but less uniform Increasing in strategic sectors

The EAPO route can lower patent prosecution costs and simplify regional portfolio administration. It does not provide the enforcement predictability, regulatory transparency or patent-linkage structure associated with the U.S. system.

What generic launch scenarios are most likely?

Early launch after successful invalidity action

A generic company challenges a blocking patent, obtains a favorable judgment and launches before the nominal expiry date. This scenario depends on local court timing and enforceability.

Launch at core-patent expiry

The challenger avoids aggressive litigation and enters when the composition patent expires, while assessing secondary patents for formulation or use risk.

Carve-out launch

The generic removes a patented indication or dosing regimen from its label where local law permits. Actual infringement risk remains dependent on promotion, prescribing and product use.

Localized launch

The product launches first in one EAEU state or through a procurement channel, followed by broader expansion. This can reduce initial investment but may create parallel regulatory and supply issues.

Delayed biosimilar launch

The biosimilar is approved or technically ready but delayed by manufacturing qualification, procurement decisions, substitution rules or unresolved process patents.

How strong is the patent estate for an EAPO-market product?

Patent strength should be scored across five dimensions:

  1. Core claim validity and remaining term.
  2. Geographic coverage and national validation status.
  3. Enforceability in the target market.
  4. Regulatory relevance of the claimed product, use or process.
  5. Ability of competitors to design around the claims.

A strong estate has a valid composition or biologic claim, meaningful remaining term, enforceable national rights, clear product coverage and limited design-around options. A weak estate relies primarily on late-filed formulation or method-of-use patents, has inconsistent national coverage or faces credible invalidity arguments.

What revenue exposure exists for branded companies?

Revenue exposure is concentrated in medicines with:

  • High Russian or Kazakhstan sales
  • Material government procurement dependence
  • Limited therapeutic substitution
  • High gross margin
  • Few alternative suppliers
  • A patent expiry within three to five years
  • Significant exposure to local-currency depreciation
  • Reliance on imported active ingredients or finished products

A revenue-at-risk model should separate patent expiry from actual generic penetration. The model should incorporate approval timing, procurement cycles, local manufacturing capacity, tender discounts, substitution policy and the likelihood of multiple generic entrants.

Key Takeaways

  • EAPO is a patent organization, not a medicines regulator.
  • EAPO patents cover eight states, while the EAEU pharmaceutical system covers five.
  • A Eurasian patent can simplify prosecution but does not create uniform enforcement.
  • There is no single EAPO or EAEU equivalent to the U.S. Orange Book.
  • Generic challenges are handled through country-specific litigation and regulatory strategies.
  • Formulation, method-of-use, device and manufacturing patents can delay entry after core-patent expiry.
  • Russia is the largest commercial market, while Kazakhstan is strategically important for regional operations.
  • Local manufacturing, procurement policy and sanctions compliance can be as important as patent status.
  • Biosimilar risk is rising, but manufacturing and regulatory barriers remain substantial.
  • Product-specific launch and revenue forecasts require a patent-family and jurisdiction-level review.

FAQs

Does an EAPO patent automatically protect a medicine in all EAPO countries?

No. The patent must be validated and maintained in the relevant states, and enforcement remains national.

Can a generic obtain EAEU approval before a patent expires?

Regulatory approval and commercial launch are separate questions. Approval may be possible before expiry, but launch can create patent infringement risk depending on the country and claims.

Are EAPO patents enforceable in Russia?

Yes, where the Eurasian patent has effect in Russia. Enforcement occurs through the applicable Russian judicial and administrative mechanisms.

Do EAPO countries grant supplementary protection certificates for medicines?

There is no single EAPO-wide supplementary protection certificate regime equivalent to the EU system. Any extension or restoration mechanism must be verified under the relevant law.

Is a biosimilar approved in Russia automatically approved in Kazakhstan?

No. EAEU membership can support a common regulatory pathway, but registration, manufacturing, pharmacovigilance and market-access requirements still require product-specific compliance.

References

  1. Eurasian Patent Organization. (n.d.). Eurasian Patent Convention and Eurasian patent system. https://www.eapo.org/

  2. Eurasian Economic Commission. (n.d.). Pharmaceutical products and common rules for circulation of medicines within the Eurasian Economic Union. https://eec.eaeunion.org/

  3. Eurasian Economic Commission. (n.d.). Rules for registration and examination of medicinal products for medical use. https://eec.eaeunion.org/

  4. World Intellectual Property Organization. (n.d.). Patent cooperation and regional patent systems. https://www.wipo.int/

  5. World Health Organization. (2022). WHO guideline on evaluation of biosimilars. https://www.who.int/

  6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files/approved-drug-products-therapeutic-equivalence-evaluations

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.